Retrospective analysis shows 9% isoniazid resistance in TB patients, highlighting gaps in diagnostics and treatment protocols.
Key Points
Isoniazid resistance affected 9% of TB cases over a 3-year period, indicating a significant threat to treatment efforts in Morocco.
Among resistant strains, 63% had mutations in the katG gene, while 37% had mutations in the inhA gene, underscoring genetic diversity.
Retrospective analysis leveraged both conventional and molecular methods to assess drug resistance among 464 TB patients.
Continued epidemiological surveillance is essential to integrate molecular diagnostics for better detection of drug resistance, especially for isoniazid.